KRAS and neuroendocrine carcinoma: A targeted NGS analysis was performed on all the four different lesions (NEC, endometrioid carcinoma, ovarian endometriosis, and uterine EAH) and on a sample of normal tissue for comparison using the Human Actionable Solid Tumor Mutations QIAseq DNA Panel (DHS-101Z, Qiagen, Hilden, Germany) that analyses 22 oncogenes (BRAF, PDGFRA, EGFR, KRAS, NRAS, KIT, AKT1, ALK, CTNNB1, ERBB3, ESR1, FOXL2, GNA11, GNAQ, IDH1, IDH2, MET, RAF1, RET, ERBB2, PIK3CA, and TP53).